1,331 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by HMS Capital Management LLC

HMS Capital Management LLC acquired a new position in United Therapeutics Co. (NASDAQ:UTHR) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,331 shares of the biotechnology company’s stock, valued at approximately $477,000.

A number of other large investors have also modified their holdings of the company. Renaissance Technologies LLC increased its holdings in shares of United Therapeutics by 1.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after acquiring an additional 22,978 shares during the period. LSV Asset Management increased its stake in United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after buying an additional 436,851 shares during the period. Dimensional Fund Advisors LP increased its stake in United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after buying an additional 22,683 shares during the period. Pacer Advisors Inc. increased its stake in United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after buying an additional 92,240 shares during the period. Finally, Swedbank AB acquired a new position in United Therapeutics during the 1st quarter valued at about $97,316,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on UTHR shares. Jefferies Financial Group raised their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Finally, The Goldman Sachs Group lifted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $370.86.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 14,700 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $374.46, for a total value of $5,504,562.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $964,983.42. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, COO Michael Benkowitz sold 14,700 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $374.46, for a total value of $5,504,562.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $964,983.42. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christopher Causey sold 510 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the sale, the director now owns 3,675 shares of the company’s stock, valued at $1,384,115.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 85,022 shares of company stock worth $30,412,032 over the last ninety days. 11.90% of the stock is currently owned by insiders.

United Therapeutics Stock Up 1.6 %

NASDAQ UTHR opened at $382.77 on Wednesday. The stock has a market capitalization of $17.09 billion, a PE ratio of 16.81, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56. The company has a 50 day moving average price of $356.00 and a two-hundred day moving average price of $318.81. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $382.95.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company’s revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the company earned $5.38 earnings per share. As a group, equities analysts anticipate that United Therapeutics Co. will post 25.57 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.